Bailard Inc. Takes $1.05 Million Position in IDEXX Laboratories, Inc. $IDXX

Bailard Inc. acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent filing with the SEC. The fund acquired 1,948 shares of the company’s stock, valued at approximately $1,045,000.

Several other large investors have also added to or reduced their stakes in IDXX. Opal Wealth Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after acquiring an additional 30 shares during the period. Ameritas Advisory Services LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $36,000. WPG Advisers LLC purchased a new stake in IDEXX Laboratories in the 1st quarter worth approximately $37,000. Finally, Bank of Jackson Hole Trust boosted its holdings in IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after purchasing an additional 69 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $701.48 on Friday. The business has a 50 day moving average of $650.81 and a 200 day moving average of $585.94. The company has a market capitalization of $56.01 billion, a price-to-earnings ratio of 58.41, a PEG ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $735.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.98% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on IDXX shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a report on Tuesday, November 4th. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Morgan Stanley boosted their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $730.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.